# Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

> **NCT07167693** · PHASE1,PHASE2 · RECRUITING · sponsor: **David K Carroll** · enrollment: 60 (estimated)

## Conditions studied

- Diabetes (DM)
- Diabetic Ketoacidosis
- Ketosis Prone Diabetes
- Hyperglycaemia (Diabetic)

## Interventions

- **DRUG:** Arginine hydrochloride
- **DRUG:** Sodium Chloride 0.9%

## Key facts

- **NCT ID:** NCT07167693
- **Lead sponsor:** David K Carroll
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-19
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07167693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07167693, "Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07167693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*